In Japan, long-term business relationships are essential to business success. This presents a real challenge for international pharmaceutical and healthcare companies entering Japan.Japanese business culture places greater significance on relationships over business transactions. While in Western business, rapid business deals…
HOME > BUSINESS
BUSINESS
- Takeda Carve-Out Venture Boots Up with 250 Million Yen Seed Round
April 11, 2018
- Hisamitsu’s Japan Ethical Drug Sales Down 3.1% in FY2017
April 11, 2018
- Mitsubishi Tanabe Files with International Court for Upfront Payment Return from S. Korean Firm
April 11, 2018
- Osaka Univ. Spinout, Sumitomo Dainippon Strike Option Deal on Antibody-Inducing Peptides
April 10, 2018
- Otsuka Partners with Takara Bio to Codevelop Gene Therapy Products with Exclusive Sales Rights in Japan
April 10, 2018
- Ethical Drug Sales Up 1.0% in February: Crecon Report
April 9, 2018
- Kowa Gets High Court Backing in Livalo Patent Suit
April 9, 2018
- Alfresa to Fully Introduce Distribution Cost Analysis System; Will “Raise Reps’ Awareness of Importance of Price Negotiations”: Pres.
April 9, 2018
- Japan Generic Market Projected at 1.2 Trillion Yen in 2021: Fuji Keizai
April 6, 2018
- Takeda, DNDi to Collaborate in Visceral Leishmaniasis Drug Development
April 6, 2018
- Daiichi Sankyo Expands Cancer Collaboration with DarwinHealth
April 6, 2018
- Takeda to Divest Its Brazilian OTC, Gx Subsidiary to Local Pharma
April 6, 2018
- Zyprexa Generics Now Carry Same Indications as Originator
April 5, 2018
- Nebulized COPD Med Lonhala Magnair Now Available in US: Sunovion
April 5, 2018
- Nichi-Iko to Raise 21.2 Billion Yen for Elmed Eisai Buyout
April 5, 2018
- Nihon Medi-Physics’ Project to Develop Labeled Antibody Therapeutics Selected for AMED’s CiCLE Grant Program
April 4, 2018
- Mochida Targets Sales of 103 Billion Yen in FY2020, Adding Gastroenterology to Priority Fields: New Biz Plan
April 4, 2018
- Fycompa Filed for Label Expansion in US for Pediatric Epilepsy
April 3, 2018
- Sanofi Seeks Asthma Indication for Dupixent in Japan
April 3, 2018
- Kyorin Nabs Rights to Sanwa Kagaku’s Nocturia Drug in Japan, Asia
April 3, 2018
ページ
The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…